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The current antituberculosis vaccine, BCG, was derived in the 1920s, yet the mechanisms of BCG-induced
protective immunity and the variability of protective efficacy among populations are still not fully un-
derstood. BCG challenges the concept of vaccine specificity, as there is evidence that BCG may protect
immunized infants from pathogens other thanMycobacterium tuberculosis – resulting in heterologous or
nonspecific protection. This review summarizes the up-to-date evidence for this phenomenon, potential
immunological mechanisms and implications for improved childhood vaccine design. BCG induces func-
tional changes in infant innate and adaptive immune compartments, encouraging their collaboration in
the first year of life. Understanding biological mechanisms beyond heterologous BCG effects is crucial to
improve infant protection from infectious diseases.
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The BCG is a live attenuated strain of Mycobacterium bovis and is the only currently licensed vaccine against TB.
It is routinely administered to infants at or shortly after birth in regions where TB is endemic BCG vaccination
confers consistent efficacy against disseminated forms of TB in childhood, such as TB meningitis and miliary TB,
however, its protective efficacy against adult-type pulmonary TB varies [1,2]. Factors that have been implicated
include BCG strain, route of administration, geographical location, exposure to environmental mycobacteria and
helminth infection [3]. There is increasing evidence, especially in regions affected by a high infectious disease burden,
that apart from protecting against TB, BCGmay reduce infant mortality from unrelated infections. Here we review
the evidence for this phenomenon, discuss potential mechanisms and outline the possible implications for future
vaccine candidates.
All-cause infant mortality reduction
Observational studies reported that BCG, alone or in combination with other vaccines, might decrease the all-cause
mortality risk up to 30–50% for up to 2 years of age in West Africa [4–6], extending to up to 5 years of age in
Uganda [7]. More specifically, it was shown that immunizing low-birth-weight infants with BCG at birth could
significantly improve their survival for the first month of life because of decreased infection risk [8]. Similar findings
were reported in India, where mortality rates were lower in BCG-vaccinated infants for up to 6 months of age,
compared with the unvaccinated infant group [9]. Studies in Malawi and Guinea-Bissau also found a trend for
reduced mortality among infants vaccinated with BCG [10,11]. Although the extent of BCG-dependent nonspecific
reduction in infant mortality is difficult to evaluate, with the efficacy estimates reaching 6–72% in clinical trials
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or 2–95% in observational studies [12,13], this evidence suggests that BCG may exert a beneficial, heterologous
influence on infant survival, reducing mortality unrelated to TB.
Impact on acquisition of infectious diseases
BCG may also reduce the acquisition of nonmycobacterial infections. In Uganda, BCG-vaccinated HIV-positive
adults had lower risk of intestinal nematode infection than unvaccinated individuals [14]. BCG vaccination also
decreased risk of heterologous infections in infants. In Guinea-Bissau, BCG-immunized infants had lower rates
of neonatal sepsis and respiratory infection [8]. Similarly, hospitalization rate due to nontubercular respiratory
infections and sepsis in Spain was lower among the BCG-vaccinated children [15]. A recent analysis of infant
immunization with BCG in 33 countries suggested BCG vaccination may reduce acute lower respiratory infection
incidence by 17–37% [16]. In contrast, a randomized trial in Denmark found no association between neonatal
BCG vaccination and infection incidence [17]. The reasons for the discrepancies are not clear, although it has
been suggested that benefits of infant BCG immunization in low-income settings may be partially accounted by
lowered undiagnosed mycobacterial infection rate [18]. Such infections would be less likely in a setting with low
infectious disease burden. Together, these studies imply that nonspecific BCG effects may be particularly beneficial
in countries with high infectious disease load, reducing both the all-cause mortality and the disease incidence.
Factors potentially contributing to the heterologous effects of BCG vaccination
BCG timing & interaction with other vaccines
Some studies suggested that diphtheria-tetanus-pertussis (DTP) vaccine might affect the impact of BCG on child-
hood mortality [4,9]; implicating that other vaccines may modulate the nonspecific effects of BCG immunization
(Table 1). In contrast, a study in Burkina Faso found that risk of mortality before 2 years of age was reduced
to a similar extent in infants vaccinated with BCG-only or both BCG and DTP [5]. Vaccination timing and
sequence were suggested as potentially important to the nonspecific effects of vaccines, as studies in Senegal and
Philippines found that immunizing infants with DTP at or following BCG administration was associated with
enhanced survival [6,19–21]. Proposals were made that BCG following DTP might reduce all-cause infant mortality
even further [22–24]. The WHO Strategic Advisory Group of Experts addressed the controversy of nonspecific BCG
and DTP interactions in 2014 and concluded that the evidence for such effects was insufficient [13].
Infant age & time post-BCG vaccination
The extent to which heterologous effects of BCG vaccination are apparent may depend on age of the infant.
BCG-dependent reduction in overall infant mortality may be the most evident in the first few months of life, before
the nonspecific infant protection becomes influenced by the administration of subsequent vaccines [4,8]; however,
in other studies heterologous effects are still apparent for up to 24 months of age [5,6]. Some studies reported BCG-
associated reduction in overall mortality of children aged up to 5 years [7,25] or decrease in hospitalization rates due
to nonmycobacterial infections in children up to 14 years of age [15]. This may be a consequence of improved early
childhood survival as BCG-related reduction in hospitalization due to sepsis was the most significant in children
aged 1–4 years, diminishing in older children [15]. This implies that the heterologous BCG effects manifest soon
after immunization, but wane over time and may be the most apparent for neonates vaccinated at birth. Another
possibility is that as infants grow older, they become exposed to pathogens more frequently, with the resulting
development of the classical immunity against infectious diseases eventually overcoming the heterologous beneficial
effects of BCG.
Sex-differential effects of BCG vaccination
Some studies indicate that BCG-dependent nonspecific infant mortality reduction may be influenced by male
or female sex, females possibly benefitting from heterologous BCG effects more than males [9,26,27]. A review of
female–male twin pair datasets from Guinea-Bissau and Senegal found that the survival benefit of BCG vaccination
in females was variable, possibly due to low death rates observed among the vaccinated twin pairs [28]. No BCG-
associated survival benefit in female infants was observed over the first 8 months of life in an Indian infant
cohort [29], although this could be attributable to excess background female neonatal mortality in this region. No
sex-related differences in heterologous BCG protection were observed in Burkina Faso [5]. SAGE addressed this
issue in 2014; however, no evidence for differences in BCG-immunized female or male heterologous mortality
reduction was found [13]. Of interest, some studies indicated that BCG-vaccinated females may produce higher
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Table 1. Nonspecific infant mortality reduction by BCG and interaction with diphtheria-tetanus-pertussis.
Study Study type Vaccine schedule† BCG-vaccinated vs
unvaccinated infants
DTP-vaccinated vs
unvaccinated infants
BCG vs BCG & DTP Observed age
group
Ref.
Guinea-
Bissau
Cohort BCG & OPV at birth;
DTP at 6, 10 &
14 weeks;
MV at 9 months
Mortality rate:
At 6–12 months of age
3.9% among
BCG-vaccinated
4.9% among BCG not
vaccinated
Mortality rate:
At 7.5-12 months of
age
4.8% among
DTP-vaccinated
4.0% among DTP not
vaccinated
Mortality rate:
At 7.5–9 months of age
3.9% among BCG &
DTP;
2.5% among BCG only
At 10–12 months of
age
5.6% among BCG &
DTP;
4.1% among BCG only
Up to 5 years of
age
[4,5]
Burkina Faso Cohort BCG at birth;
DTP at 6, 10 &
14 weeks‡
Mortality before 2
years of age risk ratio§:
0.37
Mortality before 2
years of age risk ratio§:
0.23
Mortality before 2
years of age risk ratio§:
BCG & DTP vs
unvaccinated
0.34
Up to 2 years of
age
Senegal Cohort DTP-IPV at 2, 4 &
6 months¶;
BCG administered with
the first DTP-IPV;
MV at 9–10 months
Not analyzed BCG & DTP vs
unvaccinated mortality
before 2 years of age
ratio:
cohort 1¶: 0.70 cohort
2¶: 0.59 (0.46–0.74)
Up to 2 years of
age
[6]
Senegal Cohort Recommended
schedule:
BCG at birth;
DTP & OPV at 6, 10 &
14 weeks;
MV at 9 months
BCG first:
BCG vaccinated, DTP1
not yet received;
DTP1, DTP2 or DTP3
following BCG
BCG & DTP first:
DTP2 or DTP3
following BCG & DTP
simultaneously
DTP first:
BCG following DTP1,
DTP2 or DTP3
Mortality rate ratio:
0.98– BCG-vaccinated,
DTP1 not yet received
Mortality rate ratio:
1.33 – DTP1, no BCG
1.41 – DTP2, no BCG
0.63 – DTP3, no BCG
Mortality rate ratio:
0.98 – BCG-vaccinated,
DTP1 not yet received
0.96 – BCG first
0.69 – BCG & DTP first
1.10 – DTP first
Up to 24 months
of age
[21]
Guinea-
Bissau
Randomized
trial
BCG & OPV at birth;
DTP & OPV at 6, 10 &
14 weeks;
MV at 9 months;
DTP & OPV booster at
18 months;
BCG revaccination at
19 months
BCG revaccination vs no revaccination HR:
1.20 - the whole study period
BCG revaccination vs
no revaccination HR:
0.36 – DTP booster
given prior to the trial
1.78 – no DTP booster
prior to the trial
Up to 5 years of
age
[23]
India Cohort BCG at 0–12 months;
OPV at birth, 6, 10 &
14;
DTP at 6, 10 & 14 weeks
HR#:
0.62 – for
BCG-vaccinated vs no
BCG
0.44 – BCG only, no DTP
0.72 – BCG & DTP
HR#:
0.70 - DTP prior to BCG
0.44 – DTP only
Up to 6 months
of age
[9]
Philippines Cohort BCG at 0–11 weeks;
DTP & polio vaccine at
6, 10 & 14 weeks††;
MV at 9 months
BCG-vaccinated infants only. HR‡‡:
0.18 – females, no DTP
0.27 – DTP-vaccinated
females
0.32 – DTP-vaccinated
males
Up to 30 months
of age
[19]
†Vaccination timings correspond to infant age at the time of vaccination.
‡ Infants were considered unvaccinated until the age of immunization with a specified vaccine.
§Adjusted for the area, dispensary in a village, use of health services, diarrhea in the first year of life and birth season.
¶Cohort 1 vaccinated as indicated in the Vaccination Schedule section. Cohort 2 received OPV instead of IPV.
#Assumed HR for unvaccinated infants equals 1.
††Type of polio vaccine was not specified.
‡‡Assumed HR for infant males not vaccinated with DTP equals 1. The cited HR rates exclude two deaths of infants with an unknown DTP vaccination status.
§§Mortality rate ratio adjusted for most recent weight and controlled for age.
DTP1, 2 or 3: First, second or third dose of diphtheria-tetanus-pertussis vaccine; HR: Hazard ratio; IPV: Inactivated polio vaccine; MV: Measles vaccine; OPV: Oral polio vaccine.
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Table 1. Nonspecific infant mortality reduction by BCG and interaction with diphtheria-tetanus-pertussis (cont.).
Study Study type Vaccine schedule† BCG-vaccinated vs
unvaccinated infants
DTP-vaccinated vs
unvaccinated infants
BCG vs BCG & DTP Observed age
group
Ref.
India Cohort Recommended
schedule:
BCG at birth;
DTP & OPV at 2, 3 &
4 months;
MV at 9 months;
DTP & OPV booster at
18 months
Altered sequence of
BCG and DTP
vaccination:
BCG & DTP
simultaneously
BCG following DTP
Mortality rate to 1 year
of age:
2.2% in BCG only
group
3.6% in the
unvaccinated group
Mortality rate to 1 year
of age:
2.4% in DTP only group
3.6% in the
unvaccinated group
Mortality rate ratio in
the first 9–12 months
prior to receiving
MV§§:
0.11 – BCG & DTP
simultaneously and the
last in the sequence vs
DTP following BCG
0.14 - BCG & DTP
simultaneously and the
last in the sequence vs
DTP only
0.13 – BCG & DTP
simultaneously and the
last in the sequence vs
DTP as the last vaccine
in the sequence
0.27 – BCG alone or
BCG & DTP
simultaneously and the
last in the sequence vs
DTP as the last vaccine
in the sequence
Up to 5 years of
age
[24]
†Vaccination timings correspond to infant age at the time of vaccination.
‡ Infants were considered unvaccinated until the age of immunization with a specified vaccine.
§Adjusted for the area, dispensary in a village, use of health services, diarrhea in the first year of life and birth season.
¶Cohort 1 vaccinated as indicated in the Vaccination Schedule section. Cohort 2 received OPV instead of IPV.
#Assumed HR for unvaccinated infants equals 1.
††Type of polio vaccine was not specified.
‡‡Assumed HR for infant males not vaccinated with DTP equals 1. The cited HR rates exclude two deaths of infants with an unknown DTP vaccination status.
§§Mortality rate ratio adjusted for most recent weight and controlled for age.
DTP1, 2 or 3: First, second or third dose of diphtheria-tetanus-pertussis vaccine; HR: Hazard ratio; IPV: Inactivated polio vaccine; MV: Measles vaccine; OPV: Oral polio vaccine.
levels of inflammatory cytokines in response to nonmycobacterial stimuli than males at 4 weeks [30] or 1 and
12 weeks [31] postvaccination. Therefore, immunological mechanisms of heterologous effects of BCG vaccination
may be sex-dependent; however, their contribution to heterologous infant mortality is not clear.
Mechanisms implicated in heterologous BCG-vaccinated infant protection
BCG-inducible trained innate immunity
A tempting candidate to explain the heterologous effects of BCG is the phenomenon of innate immune response
training [32–34]. Originally identified in NK cells, innate memory or training enables the innate cells to respond
more rapidly and strongly to antigens unrelated to the original stimulus and was shown to be BCG-inducible
in monocytes. Pre-exposure of murine macrophages to BCG was demonstrated to increase their ability to cope
with Candida albicans infection both in vitro and in vivo [35]. In humans, monocytes of BCG-vaccinated adults
had increased expression of surface markers of activation and produced more IL-1β, IL-6, IFN-γ and TNF-α in
response to Staphylococcus aureus or C. albicans for up to 3 months postvaccination compared with monocytes
isolated before vaccination from the same adults (Figure 1) [36,37]. Interestingly, while surface receptor expression
on monocytes from BCG-vaccinated adults was upregulated for up to a year, IL-1β and TNF-α production upon
nonmycobacterial antigen stimulation diminished by this time [38]. This suggests that the most potent effects
of heterologous BCG-trained immunity manifest over the first few months post-BCG vaccination. Apart from
inducing functional, lasting monocyte changes, BCG enhanced the vaccinated adult NK cell IL-1β and IL-6
production in response to C. albicans and S. aureus for up to 3 months, also, improving T- and B-cell deficient
mice, infected with C. albicans, survival [36,39]. This is consistent with the observations that BCG-associated
reduction in all-cause infant mortality is the most significant during the first few months of life [4–5,8], implying
that BCG-trained monocyte and NK cell immunity may contribute to broad infant protection from infectious
diseases when they are the most susceptible.
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Figure 1. BCG training-induced phenotype changes in monocytes and NK cells. BCG training of human monocytes in
vitro or by vaccination increases their surface marker expression and cytokine production in response to heterologous
antigen stimulation [36,40]. In monocytes, these changes are regulated by metabolic shift from oxidative
phosphorylation to glycolysis and histone modifications [41], with increased frequency of permissive H3K4me3 and
reduced presence of inhibitory H3K9me3 at the promoters of cytokine, receptor and metabolic pathway component
encoding genes [36,37,41–43]. The left side of the diagram depicts model innate immune cells prior to the BCG training
and the right side – post-training. Enhanced cytokine production post-training is indicated by arrows. Heterologous
microorganism – secondary, nonmycobacterial infectious agent.
+ BCG – in vitro or in vivo cell training with BCG.
TLR4: Toll-like receptor 4; H3K4me3: Trimethylation of lysine at position 4 on histone 3; H3K9me3: Trimethylation of
lysine at position 9 on histone 3.
Metabolic changes induced by innate immune training
Functional monocyte changes induced by BCG training have been associated with a metabolic shift from oxidative
phosphorylation to aerobic glycolysis (Figure 1). First demonstrated in monocyte in vitro training with β-glucan
phosphorylation [44]. Similar changes were observed in BCG-dependent monocyte training [41]. Peripheral blood
mononuclear cells upon heterologous stimulation than cells obtained prior to the vaccination [41]. This correlates
with the previous findings that monocytes obtained from BCG-immunized donors at these time points produce
higher cytokine levels than monocytes isolated before the immunization [36,37,42]. Of note, inhibition of mTOR
and glycolysis pathways diminished ex vivo BCG-trained human monocyte production of lactate, TNF and IL-6
upon lipopolysaccharide (LPS) challenge, supporting the role for glycolysis in the innate immune training [41].
Importantly, polymorphisms of HK2 and PFKP were associated with the ability of monocytes to be trained
and produce cytokines in response to LPS [41]. This implies BCG-inducible training may be ineffective in some
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Table 2. Impact of BCG training on histone modification patterns at the promoters of the immune and metabolic genes.
Gene Product Function Histone
modification
Impact on gene
expression
Cell type Model Ref.
TNF-α
IL-6
TNF-
IL-6
Immune responses ↑H3K4me3 Permissive Monocytes In vivo/BCG
vaccination
[36]
In vitro/BCG
training
[42]
In vitro/BCG
training
[37]
↑H3K4me3
↓H3K9me3
Permissive
Inhibitory
Monocytes In vitro/BCG
training
[41]
↓H3K9me3 Inhibitory Monocytes/
macrophages
In vitro/BCG
training
[43]
mTOR
HK2
PFKP
mTOR
Hexokinase 2
Platelet phospho-
fructokinase
Glycolysis ↑H3K4me3
↓H3K9me3
Permissive
Inhibitory
Monocytes In vitro/BCG
training
[41]
GLS
GLUD†
Glutaminase
Glutamate
dehydrogenase
Glutaminolysis ↑H3K4me3
↓H3K9me3
Permissive
Inhibitory
Monocytes In vitro/BCG
training
[41]
†H3K4me3 pattern change not significant upon BCG training.
H3K4me3: Trimethylation of histone 3 at lysine 4; H3K9me3: Trimethylation of histone 3 at lysine 9; BCG:  -irradiated BCG.
individuals with metabolic component polymorphisms. Other pathways may be involved in innate immune
training. Monocytes trained in vitro with BCG or oxidized low-density lipoprotein (oxLDL) were shown to
increase reactive oxygen species production upon stimulation with zymosan, a yeast-derived ligand of TLR2 [45].
BCG enhanced IL-6 and TNF-α production in histone 3 lysine 4 trimethylation dependent manner, this effect
is also demonstrated for oxLDL [36,42]. Interestingly, oxLDL stimulated monocyte scavenger receptor and CD36
expression and differentiation to foam cells [46]. Mycobacteria can interfere with the host’s lipid metabolism and
drive foam cell formation [47], suggesting that BCGmay also exploit lipid metabolism to induce monocyte training.
Epigenetic regulation of innate immune training
Epigenetic mechanisms, largely, histone modifications, regulate monocyte training (Figure 1 & Table 2). For exam-
ple, enhanced surface activation marker and inflammatory cytokine expression upon nonmycobacterial stimulation
of monocytes from BCG-vaccinated adults was associated with intracellular nucleotide sensor NOD2 dependent
H3K4 trimethylation of promoters of genes encoding these monocyte markers and cytokines [36,42]. In addition,
active promoters of β-glucan-trained monocytes contained higher levels of permissive histone modifications, such
as H3K4me3 and histone 3 lysine 27 acetylation than promoters in untrained monocytes [44]. The accumulation
of these epigenetic markers of promoter activation at the glycolysis and mTOR pathway component genes implied
cellular metabolism in innate immune training [44]. BCG-inducible monocyte training enriched the activating
H3K4me3 modification at mTOR, glycolytic enzyme, tnf and il-6 gene promoters [41]. However, the regulatory
patterns of training-related histone modifications seem to be complex as mTOR or glutamine pathway inhibition
cancelled H3K4me3 accumulation at the cytokine promoters [41]. Importantly, not only the permissive, but also
inhibitory histone modifications, such as histone 3 lysine 9 trimethylation regulate glycolysis and mTOR pathway
component or inflammatory cytokine expression in BCG-trained cells [41,43]. BCG training was shown to suppress
H3K9me3 mark while inhibition of glutamine or mTOR pathways enhanced the accumulation of this mark at
the inflammatory cytokine promoters [41]. This suggests that enzymes managing histone modification patterns may
respond to intracellular metabolite changes, coordinating cytokine or other gene expression accordingly.
Infant BCG immunization & innate immune training
The evidence on whether BCG induces trained innate immunity in infants and if it contributes to their protection
from nonmycobacterial pathogens is somewhat controversial. Although adult BCG vaccination or in vitro training
models suggest that BCG primes monocytes to increase surface activation markers and type 1 cytokine production
in response to heterologous antigen stimulation [36,37,42], infant immune responses to BCG seem more difficult
to define. Differently from adults, no differences in monocyte surface activation marker expression were observed
upon whole blood stimulation with heterologous stimuli in the BCG-immunized infant group versus unvaccinated
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controls [40]. However, Pam3CSK4 stimulation upregulated NK cell activation marker CD69 in the vaccinated
infant samples, implying that NK cells may mediate heterologous BCG effects in infants, similar to the NK
cells of the BCG-vaccinated adults [39]. Likewise, in agreement with the adult studies, whole blood samples from
BCG-immunized low-birth-weight infants produced more TNF-α, IFN-γ, IL-1β and IL-6 upon Pam3CSK4
stimulation compared with the unvaccinated infants (Table 3) [30]. Yet, different cytokine profile was identified in
BCG-vaccinated UK infant whole blood cultures, with higher levels of EGF, IL-6, PDGF-AB/BB in response to
Pam3CSK4, C. albicans and S. aureus challenge compared with the control group [40]. Previous studies explored
narrower cytokine profiles [30,36,37], so it is not clear if discrepancies reflect differences in the adult and the infant
immune systems or diverse study design.
Other studies did not confirm the association between infant BCG vaccination status and heterologous immune
responses. In contrast to previous findings, no TNF-α production changes at 1 and 12 weeks postimmunization
were found in BCG-vaccinated Gambian infants upon their PBMC stimulation with heterologous microorganisms
(Table 3) [31]. In addition, no significant changes in cytokine responses to nonspecific stimuli were observed at 3
and 13 months postrandomization in whole blood samples obtained from the BCG-vaccinated infants compared
with the controls in Denmark [51]. The reasons for the discrepancies among the findings from different studies
are not clear, although potentially low immunogenicity of BCG used in some studies was suggested as a possible
cause [31,51,52]. In Uganda, maternal BCG scar was associated with stronger inflammatory responses in infants
upon whole blood culture stimulation with TLR agonists [53], suggesting that maternal BCG status could affect
infant responses. Differences in the vaccination schedules, study design or infant populations may also contribute
to diverse outcomes in such studies.
BCG & other innate immune responses
Other mechanisms may contribute to the heterologous BCG effects. BCG-dependent immune training was shown
to elevate levels of IL-6, TNF-α and IL-1β in BCG-vaccinated adults and infants 2 weeks to several months
postvaccination in response to heterologous stimuli [30,36,37,40,42]. These cytokines can mediate the acute phase
responses, suggesting that BCG-primed immune system might exploit plasma iron regulation upon encounter with
infectious microorganisms. However, a study of Gambian neonates found no association between the vaccination
status and plasma iron, hemoglobin, hepcidin, ferritin or IL-6 levels in the unvaccinated controls and neonates
vaccinated with oral polio vaccine, HBV and BCG at birth or given BCG at 5 days of age [54]. The authors
argued that early responses were measured, potentially missing out BCG-dependent nonspecific effects and that the
observed neonate plasma levels of IL-6, hepcidin and ferritin were elevated irrespective of immunization status as a
consequence of the birth process, potentially masking the nonspecific effects of BCG [54]. Further studies exploring
a possible relationship between the acute phase responses in infants and nonspecific effects of BCG would be of
interest.
BCG-enhanced heterologous T-cell responses
BCG may steer the immune system toward Th1-type proinflammatory cytokine production, activating monocytes
and alveolar macrophages, so mediating classical antimycobacterial effects. However, this effect may extend beyond
mycobacterial specificity. In mice, BCG immunization enhanced protection from vaccinia virus via increased
CD4+ T-cell IFN-γ production [55]. Studies on human infant responses to BCG show similar effects (Table 3).
BCG-Denmark improved IFN-γ and IL-10 responses to tetanus toxoid at 12 months of age in a Ugandan
infant cohort [49]. In Philippines, infants, given BCG at birth, had higher frequencies of tetanus toxoid specific
PBMCs producing IFN-γ and CD4+ memory T cells secreting IFN-γ and TNF-α upon phytohemagglutinin
stimulation [52]. In Guinea-Bissau, BCG-vaccinated infants produced more IFN-γ than unvaccinated controls
upon whole blood stimulation with phorbol myristate acetate [30]. PBMCs from Gambian infants vaccinated with
BCG at birth produced higher levels of IFN-γ, IL-5 and IL-13 in response to hepatitis B surface antigen, and their
lymphocytes were more proliferative compared with the cells from control infants [48]. Increased IFN-γ-producing
CD8+ T-cell frequency upon C. albicans stimulation at 1 week post-BCG immunization was observed in another
Gambian infant cohort, although this effect subsided by 12 weeks postvaccination [31]. This study also reported
reduced IL-10 production in response to LPS and increased IFN-γ/IL-10 ratio upon S. pneumoniae stimulation
in BCG-vaccinated females at 12 weeks postimmunization [31]. Together, these studies suggest that BCG vaccine
may enhance maturation of Th1 cells with diverse specificities, improving responses to a broad range of microbial
or childhood vaccine antigens. As infant immune responses shift from Th17-like toward Th1-type in the first year
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Table 3. Heterologous effects of BCG on cytokine production, cell surface marker expression and proliferation.
Study Vaccine schedule† Assay Age at
observation
Secondary
stimulus
BCG vs control
Cytokine production Surface
marker
expression
Proliferation Ref.
The Gambia BCG-Pasteur at birth
or
BCG at 2 months
HBV at birth, 2 &
4 months;
OPV at birth, 1, 2 &
3 months;
DTP at 2, 3 & 4 months
control – BCG at
4.5 months
PBMCs At birth, 2 &
4 months
HBsAg ↑IFN- , IL-5 and IL-13
at 2 and 4.5 months of
age in infants given
BCG at birth
↑IL-5 and IL-13 at
4.5 months of age in
infants given BCG at
2 months
↑Lymphocyte
proliferation at 2 and
4.5 months in infants
given BCG at birth
↑lymphocyte
proliferation at
4.5 months in infants
given BCG at 2 months
[48]
TT ↑IL-5 at 4.5 months of
age in infants given
BCG at 2 months
↑IL-13 at 4.5 months of
age in infants given
BCG at birth or
2 months
No lymphocyte
proliferation changes
Uganda BCG-Bulgaria,
BCG-Denmark or
BCG-Russia at birth;
OPV at birth, 6, 10 &
14 weeks;
DTP, Hib and HBV
MV at 9 months
Whole blood 12 months TT ↑IFN- in infants given
BCG-Denmark
↑IL-10 in infants given
BCG-Bulgaria or
BCG-Denmark
[49]
PHA ↑IFN- , IL-10, IL-13 in
infants given
BCG-Denmark
South Africa BCG-Denmark at birth
control – BCG at
8 weeks
Whole blood 8 & 14 weeks SEB n.s. ↑CD4+ T-cell
proliferation at
14 weeks
[50]
BP ↑IL-2 + CD8+ T cells at
8 weeks
↑IL-13 + CD4+ and
CD8+T cells at
14 weeks
Guinea-
Bissau
OPV at birth;
BCG-Denmark at birth;
Penta at 6 weeks
control - BCG at
6 weeks
Whole blood 4 weeks Pam3CSK4 ↑IL-1, IL-6, TNF-,
IFN-
[30]
PMA &
ionomycin
↑IL-6, IFN-
The Gambia OPV & HBV at birth;
BCG-Russia at 6 weeks;
Penta, PCV-13 & OPV at
8, 12 & 16 weeks;
control – BCG at
18 weeks
PBMC 6, 7 &
18 weeks
LPS ↓IL-10 in females at
18 weeks‡
[31]
PMA &
ionomycin
↓IFN- in females at
18 weeks‡
Candida albicans ↑IFN- + CD8+ T cells
in males and females
at 7 weeks‡
S. pneumoniae ↑IFN-/IL-10 ratio in
females at 18 weeks‡
†Vaccination timings correspond to infant age at time of vaccination.
‡These timings correspond to the timing before the BCG vaccination, 1 week and 12 weeks post-BCG vaccination, respectively.
Pam3CSK4: S)-(2,3-bis(palmitoyloxy)-(2RS) -propyl)- N-palmitoyl-(R)-Cys-(S)-Ser(S)-Lys4-OH trihydrochloride, PCV-13, Penta: Diphtheria-pertussis-tetanus-Haemophilus influenzae b –
HBV. Due to DiTeKiPol/Act-Hib availability issues, 26 BCG-vaccinated and 48 control infants received Infanrix Hexa. DiTeKiPol/Act-Hib contains diphtheria toxoid, TT, polio virus types
1-3, H. influenzae type b polysaccharide. Infanrix Hexa also contains hepatitis B surface antigen and lower content of pertussis toxoid and aluminium [63].
BP: Whole cell Bordetella pertussis; CL075: TLR7/8 agonist; DTP: Diphtheria-tetanus-pertussis; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B vaccine; MV: Measles vaccine; n.s.:
Not significant; OPV: Oral polio vaccine; PBMC: peripheral blood mononuclear cells; PHA: Phytohaemagglutinin; PMA: Phorbol myristate acetate; Polio 1–3: Poliovirus types 1–3 antigen;
PPD: Purified protein derivative; Prevenar 13: 13-valent pneumococcal conjugate vaccine; SEB: Staphylococcal enterotoxin B; TT: Tetanus toxoid.
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Table 3. Heterologous effects of BCG on cytokine production, cell surface marker expression and proliferation (cont.).
Study Vaccine schedule† Assay Age at
observation
Secondary
stimulus
BCG vs control
Cytokine production Surface
marker
expression
Proliferation Ref.
United
Kingdom
BCG-Denmark at
6 weeks control – no
BCG
Whole blood 4 months
postvaccina-
tion
LPS ↑IL-8
↓GM-CSF, GRO
[40]
Pam3CSK4 ↑EGF, IL-6,
PDGF-AB/BB, MCP-3,
IL-7, IL-10, IL-12p40,
sCD40L, eotaxin,
MIP-1
↑CD69 on NK
cells
C. albicans ↑EGF, IL-6,
PDGF-AB/BB, MCP-3
↓IL-2, IL-13, IL-17, IP-10
Staphylococcus
aureus
↑EGF, IL-6, PDGF-AB/BB
Escherichia coli ↑EGF
↓GM-CSF, GRO
Denmark BCG-Denmark at
0–7 days;
DiTeKiPol/Act-Hib§ &
Prevenar 13 at 3, 5 &
12 months control – no
BCG
Whole blood 4 days, 3 &
13 months
postrandom-
ization to
BCG or
control
groups
C. albicans ↑TNF-/IL-10 at
13 months
[51]
Philippines BCG at 0–2 weeks
r
BCG after the first DTP
& OPV dose
PBMCs 2–3 months TT ↑IFN- + PBMCs in
infants vaccinated at
0–2 weeks
[52]
Polio 1–3 ↑IFN- + PBMC trend
in infants vaccinated at
0–2 weeks
PMA &
ionomycin
↑IFN- + TNF- +
CD45RO + CD4+ T cells
in infants vaccinated at
0–2 weeks
†Vaccination timings correspond to infant age at time of vaccination.
‡These timings correspond to the timing before the BCG vaccination, 1 week and 12 weeks post-BCG vaccination, respectively.
Pam3CSK4: S)-(2,3-bis(palmitoyloxy)-(2RS) -propyl)- N-palmitoyl-(R)-Cys-(S)-Ser(S)-Lys4-OH trihydrochloride, PCV-13, Penta: Diphtheria-pertussis-tetanus-Haemophilus influenzae b –
HBV. Due to DiTeKiPol/Act-Hib availability issues, 26 BCG-vaccinated and 48 control infants received Infanrix Hexa. DiTeKiPol/Act-Hib contains diphtheria toxoid, TT, polio virus types
1-3, H. influenzae type b polysaccharide. Infanrix Hexa also contains hepatitis B surface antigen and lower content of pertussis toxoid and aluminium [63].
BP: Whole cell Bordetella pertussis; CL075: TLR7/8 agonist; DTP: Diphtheria-tetanus-pertussis; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B vaccine; MV: Measles vaccine; n.s.:
Not significant; OPV: Oral polio vaccine; PBMC: peripheral blood mononuclear cells; PHA: Phytohaemagglutinin; PMA: Phorbol myristate acetate; Polio 1–3: Poliovirus types 1–3 antigen;
PPD: Purified protein derivative; Prevenar 13: 13-valent pneumococcal conjugate vaccine; SEB: Staphylococcal enterotoxin B; TT: Tetanus toxoid.
of life [56], intensifying this process through BCG vaccination may contribute to heterologous infant protection
from infectious diseases (Figure 2). However, this effect may be limited as no difference in HBsAg-specific IFN-γ
producing PBMC frequencies was found in BCG-vaccinated and control infants in Philippines [52], suggesting that
BCG did not affect responses to hepatitis B vaccine in this population.
BCG may modulate heterologous responses in other T-cell populations – C. albicans and S. aureus boosted
IL-17 and IL-22 production at 2 weeks and 1 year postimmunization in BCG-vaccinated adults [38]. Whole
blood samples from BCG-immunized infants produced less IL-13 and IL-17 upon C. albicans stimulation at
4 months postimmunization than samples from unvaccinated controls [40]. Increased fraction of IL-2-producing,
proliferating CD8+Bordetella pertussis-specific T cells was found in BCG-vaccinatedHIV-exposed uninfected South
African infants compared with the control group [50]. This suggests that BCG may also regulate Th17, Th22 or
cytotoxic T-lymphocyte subsets. It is not clear how BCG might exert this effect, but, persisting in an infant, it may
prolong activation of the innate system and provide continuous cytokine signals for T-cell activation. Dendritic
cells, innate lymphocytes and conventional T cells can make IL-22, while IL-1β or IL-6 can promote its secretion,
mediating immune responses to respiratory pathogens and fungal infections [57], implying that trained immunity
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Figure 2. A model of cell populations mediating BCG-vaccinated infant heterologous responses. The diagram shows
the innate and adaptive immune cells implicated in nonspecific infant protection and the likely timings for their
involvement with respect to BCG vaccination and infant age. At of or immediately after BCG-vaccination, monocytes
and NK cells of young infants are ‘untrained’, by low surface receptor expression or cytokine production. Once these
cells become ‘trained’ by BCG, they increase surface receptor expression and inflammatory cytokine production and
may cope with childhood infections more readily [30,36,40]. This effect diminishes over time, subsiding by 1 year
postvaccination [38]. BCG, however, induces mycobacteria-specific Th1 or CTL responses [30,40]. BCG-supported
heterologous T-cell responses may enhance trained innate immune responses from several weeks postimmunization
and provide heterologous protection from childhood infections once trained innate immunity fades. The impact of
BCG on heterologous B-cell responses is not yet clear, the current evidence being contradictive.
CTL: Cytotoxic T-cell; Mo: Monocyte; Th1: T-helper cell 1; Th17: T-helper cell 17. The role of other cells in trained
immunity or heterologous adaptive responses is not well characterized yet and is therefore not presented.
and heterologous T-cell responses may complement one another mediating BCG-dependent heterologous infant
protection from infections. Importantly, trained innate immunity wanes over time: PBMCs from BCG-vaccinated
adults produce less TNF-α and IL-1β in response to C. albicans and LPS at 1 year postimmunization [38]. However,
BCG-vaccinated infant protection from all-cause mortality extends for several years [4–7] or until adolescence [15].
Although improved neonatal or infancy survival can contribute to the long-term survival rates, the adaptive immune
responses may take over heterologous infant protection from childhood infections once the trained immunity effect
diminishes (Figure 2).
Potential mechanisms beyond heterologous protection from infectious diseases & cancer
As well as reducing all-cause infant mortality, BCG may decrease the development of some cancers. A case-cohort
study in Denmark suggested that BCG may reduce a risk of lymphoma [58]. Applied as a therapy against bladder
cancer, BCG reduced patient mortality, tumor progression and recurrence for up to 10 years, however, this effect
tended to decrease over time [59]. Infant protection from nonmycobacterial infections may share some mechanisms
with BCG-dependent antitumor effects, with trained immunity implicated in BCG immunotherapy against bladder
cancer [37]. Polymorphisms of autophagy gene ATG2B limited the ability of BCG-trained monocytes to improve
IL-1β, IL-6 and TNF-α production upon heterologous stimulation in vitro and in vivo and correlated with increased
tumor progression and recurrence in bladder cancer patients treated with intravesical BCG [37]. Cytokines promoted
by innate training, for example, IL-1β, IL-6 and TNF-αwere suggested tomediate the anticancer effects of BCG [59],
implicating overlap between BCG-mediated nonspecific protection from infectious diseases and cancer. Increased
frequencies of T helper cells and IL-2, IL-12, TNF-α, IFN-γ and IL-10 production may also mediate the anticancer
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Table 4. Influence of BCG on antibody responses to Expanded Program for Immunization vaccines.
Study Vaccine schedule† Age at observation BCG vs Control Ref.
The Gambia BCG-Pasteur at birth
or
BCG at 2 months
HBV at birth, 2 & 4 months;
OPV at birth, 1, 2 & 3 months;
DTP at 2, 3 & 4 months control – BCG at 4.5 months
At birth, 2 & 4 months ↑HBs at 2 and 4.5 months of age in infants
vaccinated with BCG at birth
↑PV1 at 4.5 months of age in infants
vaccinated at 2 months of age
[48]
Australia BCG-Denmark, BCG-Japan or BCG-Russia at birth;
HBV at birth;
PCV-7, Infanrix Hexa‡ & Rota Teq§ at 2, 4 & 6 months;
control – no BCG
4 weeks after the last
immunization
↑Pn against serotypes 9v & 18c trend for
↑Pn against serotype 6b
↓HBs
[61]
South Africa BCG-Denmark & OPV at birth;
TETRActHib, HBV & OPV at 6, 10 & 14 weeks;
MV at 9 months control – BCG at 14 weeks
14, 24 and 52 weeks No differences in levels of Hib, PT, TT
and HBs antibodies
[62]
The Gambia OPV & HBV at birth;
BCG-Russia at 6 weeks of age;
Penta¶, PCV-13 & OPV at 8, 12 & 16 weeks control – BCG
at 18 weeks
6, 7 & 18 weeks No differences in levels of PV1, PV2,
HBs, DP, PT and TT antibodies
[31]
Denmark BCG-Denmark at 0–7 days;
DiTeKiPol/Act-Hib# & Prevenar 13 at 3, 5 & 12 months
control – no BCG
13 months No differences in levels of IgG against PT,
DP, TT, Hib or Pn against serotypes 4,
6b, 9v, 14, 18c, 19f, 23f
[63]
†Vaccination timings correspond to infant age at time of vaccination.
‡DTP-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine.
§Oral pentavalent rotavirus vaccine.
¶Penta – diphtheria-pertussis-tetanus-H. influenzae b – HBV.
#Due to DiTeKiPol/Act-Hib availability issues, 44 BCG-vaccinated and 51 control infants received Infanrix Hexa.
DP: Antidiphtheria; HBs: Anti-HBsAg; Hib: Anti-H. influenzae; PV1: Antipoliovirus type 1; Pn: Antipneumococcal; PT: Antipertussis; TT: Antitetanus; DTP: Diphtheria-
tetanus-pertussis vaccine; HBV: Hepatitis B vaccine; MV: Measles vaccine; OPV: Oral polio vaccine; PCV-7: 7-valent pneumococcal vaccine.
effects of BCG [58,59], suggesting the involvement of heterologous T-cell responses, similar to the observations on
heterologous infant protection from infectious diseases (Table 3).
Influence of BCG on humoral responses to nonmycobacterial stimuli
Few studies explored the impact of BCG vaccination on humoral responses to heterologous antigens, however, in
adults, BCG was shown to boost antibody titres against influenza vaccine [60]. Infants given BCG at birth also
had higher antibody levels to HBsAg and to polio antigens than infants whose BCG vaccination was delayed
(Table 4) [48]. Elevated serum antibody concentrations to pneumococcal antigens were found in BCG-immunized
Australian infants compared with the control group, although, contrary to the previous findings, lower anti-HBsAg
IgG levels were detected in the BCG-vaccinated group [48,61]. This study also observed a trend for increased
concentrations of IgG against Haemophilus influenza and tetanus toxoid antigens [61]. Although these studies
suggest BCG may have nonspecific effects on antibody production to other childhood vaccines, other findings
maintain the controversy over the influence of BCG on heterologous antibody titres or function. No differences
in levels of antibodies to Expanded Program for Immunization (EPI) vaccine antigens were found at 12 weeks
postimmunization in BCG-vaccinated Gambian infants compared with the controls [31]. Similarly, no differences
in titres of antibodies against H. influenza, pertussis, tetanus and hepatitis B antigens were found in South African
infants immunized at birth compared with the group in which BCG immunization was delayed [62]. A recent trial
in Denmark found no association between the BCG vaccination status and antibody titres against other childhood
vaccine antigens at 13 months of age [63]. Possibly, timing of BCG vaccination during early immune system
development phases may influence its nonspecific effects on antibody responses, as BCG may have contributed to
elevated antibody titres against H. influenza, pertussis and several pneumococcal antigens in infants vaccinated at
2–7 days postbirth [63]; however, the extent of this effect is not clear. Variation in BCG strains, EPI vaccines or
immunization schedules applied in individual studies may also influence infant humoral responses. Reducing their
impact in future studies may be necessary to establish whether BCG influences antibody responses to other EPI
vaccines or childhood infections.
future science group www.futuremedicine.com 1203
Review Butkeviciute, Jones & Smith
Conclusion & future perspective
A large body of evidence suggests that BCG vaccination provides protection from diseases other than TB and that
it may modulate the immune responses to other childhood vaccines. Several important implications for BCG and
other vaccines that may exert similar beneficial heterologous effects arise from these findings.
First, the immunological mechanisms beyond heterologous infant protection from infectious diseases are not
understood. Although BCG or other live vaccines, such asMMR vaccine may broadly enhance monocyte activation
status and function or proinflammatory, Th1-polarizing responses [64], or modulate antibody responses [48,61], the
data on immune mechanisms beyond heterologous infant protection from infections are inconsistent.
To overcome this, future immunological studies or randomized trials exploring the heterologous effects of
BCG and their immunological mechanisms in infants may need to reduce variation in vaccination schedules or
observation timings. Although this is difficult to conduct in real-life settings, it would allow for more comparability
between the studies and their outcomes. In addition, despite the controversies, future studies need to address the
issue of potential vaccine interactions to ensure optimal infant protection from infectious diseases.
Executive summary
All-cause infant mortality reduction
• BCG reduces all-cause infant mortality, unaccounted by reduction in mycobacterial infections alone.
Impact on acquisition of infectious diseases
• BCG may decrease the risk of nonmycobacterial sepsis and respiratory infections among the vaccinated infants.
Factors potentially contributing to the heterologous BCG effect manifestation
• Heterologous effects of BCG may be modified by interactions with other vaccines, such as
diphtheria-tetanus-pertussis; however, the evidence for this is controversial.
• BCG can significantly decrease all-cause infant mortality and infectious disease acquisition in young infants;
however, this effect can extend throughout childhood and adolescence.
• The sex of an infant may influence heterologous BCG protection from infectious diseases, with some studies
reporting that female infants may benefit more from BCG-immunization; however, the evidence for such an
effect is mixed.
Mechanisms implicated in heterologous BCG-vaccinated infant protection
• BCG may enhance maturation of infant Th1 responses and monocyte and NK cell ability to cope with a broad
spectrum of pathogens for prolonged time periods.
• It may do so via innate immune training, a process characterized by metabolic, cytokine production and surface
marker changes in monocytes and NK cells.
• During innate immune training with BCG, trained cells undergo a metabolic shift from oxidative phosphorylation
to glycolysis.
• In parallel, changes in epigenetic regulation occur in BCG-trained cells, with accumulation of gene expression
activating histone modifications accumulating at the promoters of genes encoding IL-1β, IL-6 and TNF-α,
glycolytic pathway components and surface receptors.
• The evidence for the presence of immunological mechanisms associated with trained immunity in BCG-vaccinated
infants is mixed, with some studies reporting enhanced NK cell activation, elevated TNF-α, IL-1β, IL-6, IFN-γ, EGF
or PDGF-AB/BB production upon heterologous stimulation; however, other studies found no association between
BCG immunization and heightened innate immune responses.
• Improved heterologous Th1-like responses, with increased TNF-α and IFN-γ production in response to Expanded
Program for Immunization vaccine antigens were reported in multiple sites, including Uganda, Guinea-Bissau,
The Gambia or Philippines.
• As BCG-vaccinated individual IL-1β and TNF-α production in response to innate immunity stimuli subsides by
1 year postimmunization, heterologous BCG-dependent T-cell activation can contribute to or maintain
nonspecific BCG effects once trained immunity benefits wane.
• BCG may modulate infant humoral responses to other immunizations, elevating or decreasing antibody levels to
such vaccines as hepatitis B or pneumococcal conjugate vaccines; however, further studies are needed to
determine the extent of this effect.
Conclusion & future perspective
• Multiple epidemiological and immunological studies confirm that BCG exerts broad, beneficial effects in the
vaccinated individuals protecting them from diseases other than TB.
• Trained immunity enhanced heterologous T-cell responses and, possibly, modulated antibody responses to other
vaccines may mediate the nonspecific effects of BCG.
• Further work is needed to address the role of these factors on BCG and other childhood vaccine dependent
heterologous effects and define the underlying mechanisms.
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Further work needs to address how BCG or other childhood immunizations regulate T- and B-cell subsets of
diverse antigen specificities and which memory or effector cell fractions they maintain or promote to proliferate.
In parallel, the role of the innate immune responses in mediating the nonspecific effects of BCG, MMR or other
vaccines needs to be studied more extensively. It would also be interesting to test if other cell types could be involved
in heterologous infant protection from all-cause mortality or infections. Together, this knowledge may be exploited
for improving anti-TB and other childhood vaccine design.
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